Skip to main content
Journal ArticleOPEN ACCESS

Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel

Clinical Infectious Diseases (2021) 73(6) E1376-E1379
DOI: 10.1093/cid/ciab361
68Citations
Citations of this article
77Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In a large cohort of United States healthcare personnel without prior coronavirus disease 2019 (COVID-19) infection, 94 382 doses of messenger RNA (mRNA) COVID-19 vaccine were administered to 49 220 individuals. The adjusted vaccine effectiveness following 2 doses of each of the 2 available brands of mRNA vaccine exceeded 96%.

Author supplied keywords

Cite

CITATION STYLE

APA

Swift, M. D., Breeher, L. E., Tande, A. J., Tommaso, C. P., Hainy, C. M., Chu, H., … Virk, A. (2021). Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel. Clinical Infectious Diseases, 73(6), E1376–E1379. https://doi.org/10.1093/cid/ciab361

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free